Broker tips: HSBC, Shire, Aviva
30th Sep 2015 15:06
(ShareCast News) - UBS upgraded HSBC to 'buy' from 'neutral' saying the risk/reward on the shares has shifted to the upside. It noted that since 11 August when the PBoC unexpectedly weakened the renminbi, HSBC's share price has dropped 15-20%, equivalent to a decline of around $30bn in market cap.
Read moreHSBC upgrades Shire but concerns remain over lifitegrast, Baxalta
30th Sep 2015 11:34
(ShareCast News) - HSBC upgraded Shire to 'hold' from 'reduce', noting that the shares have fallen below its unchanged price target of 4,734p. Nevertheless, the bank said it remains concerned about the potential downside risks from a delay to approval of the lifitegrast drug, or, to a lesser extent,
Read moreAppeals court upholds Shire's patents for Vyvanse drug
25th Sep 2015 07:34
(ShareCast News) - Pharmaceuticals company Shire said late on Thursday that a US court of appeals has upheld the summary judgment ruling of the US District Court for the district of New Jersey that certain claims of the patents protecting its hyperactivity drug Vyvanse are valid. Shire's lawsuit inc
Read moreLondon close: Analysts see further downside risks for copper
21st Sep 2015 17:06
(ShareCast News) - UK stocks finished the session with slight gains, tracking the ebb and flow of trading Stateside as analysts continued to weigh in with their opinions on the US Federal Reserve's decision on 17 September to stay put. Investors were also digesting remarks from various Fed officials
Read moreBarclays upgrades Shire to overweight, highlights valuation
21st Sep 2015 16:10
(ShareCast News) - Shire chief Flemming Ornskov is still keen on pursuing inorganic growth, which analysts at Barclays believe caps downside risks in the shares. As regards the company's approach for Baxalta - which has stalled - the broker said a transaction makes sense under $55 per share, with th
Read moreFTSE 100 movers: Shire and Wolseley rally, RSA Insurance plummets as Zurich deal called off
21st Sep 2015 13:02
(ShareCast News) - The FTSE 100 was up 0.74% with the index of leading shares up 45.26 points to 6,149.37. Wolseley led the market on Monday after Credit Suisse added the stock to its European and Global Focus Lists and raised its price target to 4,900p from 4,400p. It said Wolseley has delivered
Read moreLondon midday: Investors shake off Wall Street losses, Fed remarks
21st Sep 2015 11:33
(ShareCast News) - UK stocks edged higher as investors digested a raft of remarks over the weekend from various members of the Federal Reserve and ahead of a speech from another top US central bank official scheduled for later on Monday. As of 1147 BST the Footsie was 33.45 points higher to reach 6,
Read moreShire rallies on EU approval for ADHD drug Intuniv
21st Sep 2015 08:38
(ShareCast News) - Shire was the top riser on the FTSE 100 after the pharmaceuticals company said its Intuniv drug has been awarded European approval for use as a non-stimulant drug for attention deficit hyperactivity disorder in children and adolescents for whom stimulants are not suitable. The Eur
Read moreLondon close: Stocks decline on interest rate confusion ahead of FOMC decision
14th Sep 2015 16:27
(ShareCast News) - The UK equity market declined on Monday after earlier gains as investors showed nervousness ahead the Federal Reserve's interest rate decision. The Federal Open Market Committee on Thursday announces whether it will raise rates for the first time in almost a decade following a two
Read moreLondon midday: Stocks edge higher as China unveils state-firm reforms
14th Sep 2015 11:50
(ShareCast News) - London stocks edged higher on Monday after China revealed details of state-business reforms as worse-than-expected data fuelled concerns about the nation's slowdown. China on Sunday outlined plans to restructure its state-owned enterprises, including partial privatisation. The pro
Read moreShire said to be mulling ways to sweeten bid for Baxalta
14th Sep 2015 07:35
(ShareCast News) - Pharmaceutical company Shire is reportedly mulling options to sweeten its multi-billion dollar, all-stock offer for US biotechnology group Baxalta by putting cash into shareholders' hands sooner. Last month, Dublin-based Shire made an offer that valued Baxalta at $30.6bn, but it e
Read moreLondon pre-open: Shire set to up the dose
14th Sep 2015 07:10
(ShareCast News) - Stocks were being called to start the day comfortably higher, with the Footsie set to gain 56 about points, riding on the back of Friday's gains on Wall Street. Investors thus seemed to brush off the uncertainty ahead of the US Federal Reserve's impending interest rate decision on
Read moreMerrill rates Shire a risky bet over Baxalta doubts, despite back-up plans
7th Sep 2015 10:01
(ShareCast News) - After the weekend revelation of Shire's plans for back-up acquisitions should its bid for US rival Baxalta fail, Bank of America Merrill Lynch said the drug company's reduced valuation had become attractive but near-term risks were a deterrent. The FTSE 100 pharmaceutical group ha
Read moreShire names former Dun & Bradstreet CEO as non-exec director
1st Sep 2015 08:07
(ShareCast News) - Shire said it has appointed former Dun and Bradstreet CEO Sara Mathew as a non-executive director. Mathew, who also spent 18 years at Procter & Gamble, will step into her new role on 1 September, the FTSE 100 pharmaceutical company said. "Sara is a highly-skilled global leader
Read moreShire chief seeks £1bn savings if Baxalta bid is won
30th Aug 2015 16:21
(ShareCast News) - The chief executive of pharmaceuticals giant Shire has said he will cut costs by £1bn if his new £19bn bid to acquire Baxalta is successful. Flemming Ornskov has reportedly contacted former staff of the US company to find out where costs could be best saved, the Sunday Times repo
Read more